Current Regulatory Guidance Pertaining Biomarker Assay Establishment and Industrial Practice of Fit‐for‐Purpose and Tiered Approach

[1]  Roger Hayes,et al.  Recommendations on biomarker bioanalytical method validation by GCC. , 2012, Bioanalysis.

[2]  Sarah Watson,et al.  Pragmatic issues in biomarker evaluation for targeted therapies in cancer , 2015, Nature Reviews Clinical Oncology.

[3]  H. Soares,et al.  Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report , 2005, Pharmaceutical Research.

[4]  P. Timmerman.  Biomarker assay validation: are we having the right discussions? , 2016, Bioanalysis.

[5]  Patrick Bennett,et al.  Biomarkers: more of a challenge for bioanalysis than expected. , 2016, Bioanalysis.

[6]  Naidong Weng,et al.  Overview: Fundamentals of a Bioanalytical Laboratory , 2013 .

[7]  Lauren F. Stevenson,et al.  The breadth of biomarkers and their assays. , 2016, Bioanalysis.

[8]  J Cummings,et al.  Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs , 2010, British Journal of Cancer.

[9]  A. Fourie,et al.  Quantitation of leukotriene B(4) in human sputum as a biomarker using UPLC-MS/MS. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[10]  Vinod P. Shah,et al.  Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007, The AAPS Journal.

[11]  W. Colburn,et al.  Biomarkers, Validation and Pharmacokinetic-Pharmacodynamic Modelling , 2003, Clinical pharmacokinetics.

[12]  Renuka Pillutla,et al.  2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity). , 2015, Bioanalysis.

[13]  Brian Booth,et al.  When do you need a validated assay? , 2011, Bioanalysis.

[14]  A. P. Valeri,et al.  Strategic regulatory approaches for the qualification of a biomarker assay for safety use. , 2013, Bioanalysis.

[15]  Hao Wang,et al.  Validation and application of an LC-MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  A. Fourie,et al.  A highly sensitive and selective method for the determination of leukotriene B4 (LTB4) in ex vivo stimulated human plasma by ultra fast liquid chromatography-tandem mass spectrometry. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[17]  A. D. Rodrigues,et al.  Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. , 2014, British journal of clinical pharmacology.

[18]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[19]  Steve Lowes,et al.  AAPS and US FDA Crystal City VI workshop on bioanalytical method validation for biomarkers. , 2016, Bioanalysis.

[20]  Stephanie Cape,et al.  2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV) (Part 1 - small molecules, peptides and small molecule biomarkers by LCMS). , 2016, Bioanalysis.

[21]  Surinder Kaur,et al.  2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 - hybrid LBA/LCMS and input from regulatory agencies). , 2015, Bioanalysis.

[22]  Richard Houghton,et al.  Conference Report: Analytical challenges in the qualification and validation of pharmacodynamic biomarkers. , 2011, Bioanalysis.

[23]  Naidong Weng,et al.  Relative quantitation of glycoisoforms of intact apolipoprotein C3 in human plasma by liquid chromatography-high-resolution mass spectrometry. , 2013, Analytical chemistry.

[24]  Eric Woolf,et al.  Workshop Report: Crystal City V—Quantitative Bioanalytical Method Validation and Implementation: The 2013 Revised FDA Guidance , 2014, The AAPS Journal.

[25]  N. Weng,et al.  Tiered Approaches to Chromatographic Bioanalytical Method Performance Evaluation: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team , 2014, The AAPS Journal.

[26]  Philip Timmerman,et al.  Tiered approach revisited: introducing stage-appropriate or assay-appropriate scientific validation. , 2014, Bioanalysis.

[27]  T. Ward,et al.  Fit-for-purpose biomarker method validation in anticancer drug development. , 2010, Drug discovery today.

[28]  Naidong Weng,et al.  Important considerations for quantitation of small-molecule biomarkers using LC-MS. , 2012, Bioanalysis.

[29]  Naidong Weng,et al.  Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity , 2016, The AAPS Journal.

[30]  S. Bates,et al.  European Bioanalysis Forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development. , 2012, Bioanalysis.

[31]  William D. Figg,et al.  Validation of Analytic Methods for Biomarkers Used in Drug Development , 2008, Clinical Cancer Research.

[32]  K. Cowan.  Implementing fit-for-purpose biomarker assay approaches: a bioanalytical perspective. , 2016, Bioanalysis.